QuarterHawk — Equity ResearchQuarterHawk — Equity Research

DENTSPLY SIRONA Inc. (XRAY)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore 2 is below the required floor of 3, so no bullish entry is admissible regardless of the chart; the technical read is independently weak (9.16 below SMA20 9.48, SMA50 9.43 and SMA200 11.19 with MACD histogram -0.03), and both entry types were considered and rejected — no breakout stop qualifies (the overhead 9.85 swing high is unsettled resistance with momentum rolling over) and no pullback limit qualifies (no higher-low support structure to bid against).

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment and consumable products globally. It operates through segments including Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers a range of dental and medical devices, including imaging equipment, dental handpieces, and catheters.

Fundamental

fair
Fundamental3
Mixed fundamentals

DENTSPLY SIRONA shows cash generation but faces declining revenue and high leverage.

DENTSPLY SIRONA reads as a leveraged turnaround: operating and free cash flow stay positive, the consumables franchise remains profitable and there is no going-concern, covenant-breach or near-term maturity-wall signal — but organic revenue is still contracting (about -7% constant currency in Q3-2026), adjusted EPS and adjusted EBITDA are falling year over year, net debt is about $2.1B, the company negotiated covenant relief twice in twelve months, the common dividend was eliminated in 2026, and the 2026 GAAP profit leans on a one-time accounting-estimate change and tariff refunds. Mixed risk/reward rather than a clean fundamental buy.

Sentiment

weak
Sentiment2
Negative sentiment

Sentiment is negative following an earnings miss and guidance cut.

Dominant driver is the Q3-2026 print and FY2026 guidance cut (earnings, announced, 2026-11-05) — net sales of $836M missed the $861.7M FactSet consensus, adjusted EPS fell 29.4% and the stock dropped 14.4% in a day — leaving six scored in-window items at an aggregate polarity of roughly -0.32. The sentiment delta is indeterminate because the 30-90 day baseline produced only two scorable items (+0.30 each, below the three-item threshold), and a moderate red-flag cap applies for sharply deteriorating sentiment (<=14d) with no offsetting bullish catalyst.

Technical

weak
Technical2
Bearish trend

The stock trades below key moving averages, indicating a bearish trend.

Chart read is weak-to-bearish. At 9.16 the stock trades below the SMA20 (9.48), SMA50 (9.43) and SMA200 (11.19), and below every short-lookback average (EMA9 9.52, EMA21 9.48, WMA9 9.55, WMA21 9.58, DEMA14 9.59, TEMA14 9.54) plus the 2026-11-13 daily VWAP of 9.23 — a fully bearish stack with the SMA50 under the SMA200. The 2026-11-06 capitulation-to-reversal session (low 8.14 to close 9.46 on 10.3M shares) produced a six-session bounce that failed at 9.85 on 2026-11-11 and has since rolled over to 9.16, giving back the 9.24-9.41 shelf. Momentum confirms the fade: MACD line 0.05 versus signal 0.07 leaves the histogram at -0.03 (fresh bearish cross) while RSI14 45.29 and Williams %R -61.65 offer no oversold springboard. ADX14 23.83 is direction-agnostic strength and, read with price under all averages, describes a moderate DOWN trend rather than a bullish one. ATR14 0.50 equals 5.46% of price (elevated), StdDev20 0.45. Chart quality 2 of 5: mostly neutral-to-weak with only a bounce, no bullish confirmation stack. Independently of the chart, qualitativeScore 2 is below the required floor of 3 and routes the action to Do Nothing.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.